Skip to content

Study · Observational study · n = 29 · 2024

2 results

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty.

Park KH, Gwag SH, Kim YJ, Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH

Annals of pediatric endocrinology & metabolism29 Jan 2024Cited by 5 (Europe PMC)

PMID38291760 (opens in a new tab)PMCIDPMC11220399 (opens in a new tab)DOI10.6065/apem.2346132.066 (opens in a new tab)PepBankPUB-38291760
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, triptorelin pamoate suppressed LH in 93.1% after 6 months, with suppression maintained until the final injection.

    In plain wordsIn girls with early puberty, triptorelin pamoate suppressed LH in 93.1% after 6 months.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLH suppression
    Study

    n = 29

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    LH suppression
    93.1%
    triptorelin pamoate after 6 months

    Source sentences

    Summary
    In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection.
    1 context sentence
    Summary · context
    In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment.
  2. 02HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, bone age advancement decreased during follow-up after triptorelin pamoate treatment.

    In plain wordsIn girls with early puberty, bone age advancement decreased from treatment start to one year after triptorelin pamoate treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseBone age advancement
    Study

    n = 29

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Bone age advancement
    1.8 years
    treatment start
    Bone age advancement
    0.6 years
    1-year posttreatment

    Source sentences

    Summary
    The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment.
    1 context sentence
    Summary · context
    In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.